Screener
ArriVent BioPharma, Inc. AVBP Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by ArriVent BioPharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The source filing: ArriVent BioPharma, Inc.’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:08 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-058650
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $8,727 | $5,934 |
| Accrued expenses | 16,169 | 19,997 |
| Operating lease liabilities | 99 | 14 |
| Total current liabilities | 24,995 | 25,945 |
| Operating lease liabilities, net of current amount | 320 | — |
| Total liabilities | 25,315 | 25,945 |
Item 1. Condensed Financial Statements (Unaudited):
FAQ
- What is ArriVent BioPharma, Inc.'s accrued expenses?
- ArriVent BioPharma, Inc. (AVBP) reported accrued expenses of $16.17M in Q1 2026.
- How has ArriVent BioPharma, Inc.'s accrued expenses changed year-over-year?
- ArriVent BioPharma, Inc.'s accrued expenses increased by 91.3% year-over-year, from $8.45M to $16.17M.
- What is the long-term trend for ArriVent BioPharma, Inc.'s accrued expenses?
- Over 2 years (2023 to 2025), ArriVent BioPharma, Inc.'s accrued expenses has grown at a 69.6% compound annual growth rate (CAGR), from $6.95M to $20M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.
Ask your AI about ArriVent BioPharma, Inc.'s accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude